

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Tuesday, 22 August 2017, 10am to 1pm

Venue: National Institute for Health and Care Excellence
10 Spring Gardens
London
SW1A 2BU

Present:	1. Dr Amanda Adler	Present for all notes
	2. Dr Sanjeev Patel	Present for all notes
	3. Professor John Cairns	Present for all notes
	4. Mr Mark Chapman	Present for all notes
	5. Mr Diar Fattah	Present for all notes
	6. Ms Susan Faulds	Present for all notes
	7. Mark Glover	Present for all notes
	8. Dr Sumeet Gupta	Present for all notes
	9. Mr Richard James Hoddes	Present for all notes
	10. Mr Christopher O'Regan	Present for all notes
	11. Professor Stephen Palmer	Present for all notes
	12. Dr Danielle Preedy	Present for all notes
	13. Ms Marta Soares	Present for all notes
	14. Dr Nicky Welton	Present for all notes

In attendance:

Bashama Anjum	Administrator, National Institute for Health and Care Excellence	Present for all notes
Ahmed Elsada	Technical Advisor, Technology Appraisals, National Institute for Health and Care Excellence	Present for all notes
Elisabeth George	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Anwar Jilani	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Isaac Corro Ramos	Evidence Review Group, Kleijnen Systematic	Present for notes 1 to 15

Dr Rob Riemsma	Reviews Evidence Review Group, Kleijnen Systematic Reviews	Present for notes 1 to 15
Professor Peter Clark	Chair of NHS England Chemotherapy Clinical Reference Group and National Clinical Lead for CDF – NHS commissioning expert, nominated by NHS England	Present for all notes
Dr Graham Collins	Consultant Haematologist, Oxford University Hospital – clinical expert, nominated by Roche	Present for notes 1 to 13
Geraldine Mason	Patient expert, nominated by the Lymphoma Association	Present for notes 1 to 13
Professor Andrew Pettitt	Professor and Honorary Consultant Haematologist, University of Liverpool, Royal Liverpool and Broadgreen University Hospitals – clinical expert, nominated by the NCRI-ACP-RCP-RCR	Present for notes 1 to 13
Ms Kate Robinson	Patient expert, nominated by the Lymphoma Association	Present for notes 1 to 13

Non-public observers:

Helen Barnett	Senior Medical Editor, NICE	Present for all notes
Heidi Livingstone	Senior Public Involvement Advisor, Communications, NICE	Present for all notes
Edgar Masanga	Business Analyst, Resource Impact Assessment	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020]
2. The Chair welcomed Mr Diar Fattah, Ms Susan Faulds and Mr Richard Hoddes to their first meeting as a member of the Appraisal Committee

3. Apologies were received from Dr Ray Armstrong, Dr Nigel De Kare Silver, Dr Sanjay Kinra, Dr Miriam McCarthy, Nigel Westwood and Dr Stuart Williams

Any other Business

4. The Committee were given an update on the progress of appraisals that had been discussed at previous meetings.

Appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020]

Part 1 – Open session

5. The Chair welcomed the invited experts: Professor Peter Clark, Dr Graham Collins, Geraldine Mason, Professor Andrew Pettitt, Ms Kate Robinson, Isaac Corro Ramos and Dr Rob Riemsma to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Roche to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Amanda Adler, Dr Sanjeev Patel, Professor John Cairns, Mr Mark Chapman, Mr Diar Fattah, Ms Susan Faulds, Mark Glover, Dr Sumeet Gupta, Mr Richard James Hoddes, Mr Christopher O'Regan, Professor Stephen Palmer, Dr Danielle Preedy, Ms Marta Soares, Dr Nicky Welton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020].
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020].
9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. Professor Peter Clark, Geraldine Mason, Isaac Corro Ramos and Dr Rob Riemsma declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of obinutuzumab for untreated advanced follicular lymphoma [ID1020]
 - 9.2. Dr Graham Collins declared a personal specific financial interest as he has received honoraria, speaking and consulting fees from Roche.

- 9.2.1. It was agreed that this declaration would not prevent Dr Collins from participating in this section of the meeting
- 9.3. Professor Andrew Pettitt declared a personal specific financial interest as he has received research funding and honoraria from Roche.
- 9.3.1. It was agreed that this declaration would not prevent Professor Pettitt from participating in this section of the meeting
- 9.4. Ms Kate Robinson declared a personal non-specific non-financial interest as she is part of the relevant NCRI clinical studies group.
- 9.4.1. It was agreed that this declaration would not prevent Ms Robinson from participating in this section of the meeting
10. The Chair introduced the lead team, Dr Sanjeev Patel and Mark Chapman who gave presentations on the clinical effectiveness and cost effectiveness of obinutuzumab for untreated advanced follicular lymphoma [ID1020].
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
16. The Committee continued to discuss the clinical and cost effectiveness of obinutuzumab for untreated advanced follicular lymphoma [ID1020].
- 16.1. The committee decision was based on consensus.
17. The Committee instructed the technical team to prepare the [Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

18. Wednesday, 20 September 2017, 10am to 5pm at National Institute for Health and Care Excellence, 10 Spring Gardens, London SW1A 2BU